ReviewAnnals of biomedical engineering2009
Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics.
Review in Annals of biomedical engineering, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed.
- Tuning Core Fluidity in Emulsion Nanoparticles for Stable and Transition-Metal-Free Responsive 19F MRI Probes.Journal of the American Chemical Society · 2026Article
- Kupffer Cell Capture-Evading Modifiable Sub-20 nm Lipid Nanodisc-BasedJournal of the American Chemical Society · 2026Article
- Double-Emulsion Perfluorocarbon Nanodroplets for Ultrasound and Photoacoustic Image-Guided Drug Delivery and Release.ACS nano · 2025Article
- Novel non‑metal‑based contrast agents for MR imaging: Emerging approaches and clinical perspectives (Review).International journal of oncology · 2025Review
- Perfluorocarbon nanoemulsions in drug delivery: design, development, and manufacturing.Theranostics · 2025Review
- Ginsenoside modified lipid-coated perfluorocarbon nanodroplets: A novel approach to reduce complement protein adsorption and prolongActa pharmaceutica Sinica. B · 2024Article
- Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review.International journal of molecular sciences · 2023Review
- Design of Highly Fluorinated Peptides for Cell-basedBioconjugate chemistry · 2023Article
- Simultaneous Inhibition of Thrombosis and Inflammation Is Beneficial in Treating Acute Myocardial Infarction.International journal of molecular sciences · 2023Article
- Rapamycin Perfluorocarbon Nanoparticle Mitigates Cisplatin-Induced Acute Kidney Injury.International journal of molecular sciences · 2023Article
- Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC.Molecular cancer · 2022Article
- Prognostic Value of Fluorine-19 MRI Oximetry Monitoring in cancer.Molecular imaging and biology · 2022Review
- Nanotechnology as a Versatile Tool forPharmaceutics · 2022Review
- Enhancement of tumor lethality of ROS in photodynamic therapy.Cancer medicine · 2021Review
- Fluorine (Methods in molecular biology (Clifton, N.J.) · 2021Article
- Asialoglycoprotein Receptor-Targeted Superparamagnetic Perfluorooctylbromide Nanoparticles.Contrast media & molecular imaging · 2021Article
- Perfluoropolyether Nanoemulsion Encapsulating Chlorin e6 for Sonodynamic and Photodynamic Therapy of Hypoxic Tumor.Nanomaterials (Basel, Switzerland) · 2020Article
- Fluorous Soluble Cyanine Dyes for Visualizing Perfluorocarbons in Living Systems.Journal of the American Chemical Society · 2020Article
- A fluorous biphase drug delivery system triggered by low frequency ultrasound: controlled release from perfluorous discoidal porous silicon particles.Nanoscale advances · 2020Article
- Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy: opportunities, challenges, and future development.Acta pharmaceutica Sinica. B · 2020Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A broad array of nanomaterials is available for use as contrast agents for molecular imaging and drug delivery. Due to the lack of endogenous background signal in vivo and the high NMR sensitivity of the (19)F atom, liquid perfluorocarbon nanoemulsions make ideal agents for cellular and magnetic resonance molecular imaging. The perfluorocarbon core material is surrounded by a lipid monolayer which can be functionalized with a variety of agents including targeting ligands, imaging agents and drugs either individually or in combination. Multiple copies of targeting ligands (approximately 20-40 monoclonal antibodies or 200-400 small molecule ligands) serve to enhance avidity through multivalent interactions while the composition of the particle's perfluorocarbon core results in high local concentrations of (19)F. Additionally, lipophilic drugs contained within molecularly targeted nanoemulsions can result in contact facilitated drug delivery to target cells. Ultimately, the dual use of perfluorocarbon nanoparticles for both site targeted drug delivery and molecular imaging may provide both imaging of disease states as well as conclusive evidence that drug delivery is localized to the area of interest. This review will focus on liquid perfluorocarbon nanoparticles as (19)F molecular imaging agents and for targeted drug delivery in cancer and cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.